Steve Mandel's Lone Pine Capital filed its Q4 2024 13F showing a $24 billion equity portfolio, down 8% from the prior quarter, with concentrated moves out of mega-cap technology and into defensive growth. The firm exited 11 positions entirely, including stakes in three semiconductor names, and reduced its technology weighting from 42% to 29% of assets under management. The reallocation placed $4.1 billion into healthcare and $3.1 billion into consumer discretionary, marking the largest sector rotation in Lone Pine's portfolio since mid-2022.

The firm sold its entire $1.8 billion position in a hyperscaler cloud provider and trimmed its artificial intelligence hardware exposure by 67%, retaining only a $620 million stake in one AI infrastructure play. Meanwhile, Lone Pine added $2.3 billion across four new healthcare positions, three of which are biotech firms with late-stage oncology pipelines expected to report Phase III data between April and July 2025. The consumer discretionary additions skewed toward luxury retail and travel platforms, with one new $1.4 billion position in a European luxury conglomerate that trades at 18x forward earnings, below its ten-year median of 22x.

This repositioning suggests Mandel is pricing in a shallow earnings recession for high-multiple technology, while positioning for a consumption recovery in the back half of 2025. Lone Pine has historically led sector rotations by two quarters, notably rotating out of financials in Q1 2020 and into industrials in Q4 2021, both ahead of broader peer movement. The current tilt into healthcare and discretionary aligns with a view that the Federal Reserve's rate cuts, now priced at 75 basis points by December 2025, will disproportionately benefit interest-rate-sensitive consumer spending and biotech financing conditions. The firm's healthcare weighting now sits at 34%, the highest since Q2 2019, when it preceded a 19% sector outperformance over the subsequent twelve months.

Allocators should monitor Lone Pine's Q1 2025 filing in mid-May for confirmation of whether this defensive posture persists or reverses. The firm's three new biotech positions face binary catalysts between April and July, and any early readouts will likely inform Mandel's next move. Additionally, the European luxury position represents 6% of portfolio weight, unusual concentration for Lone Pine outside its top-ten holdings, signaling conviction on a non-consensus trade. The firm's technology trimming also coincides with insider selling at two of the exited names, suggesting Mandel is tracking management signal as much as valuation.

Lone Pine managed $24 billion in long equity as of December 31, 2024, with the portfolio now split 29% technology, 34% healthcare, 18% consumer discretionary, and 19% across industrials and communication services. The firm has not disclosed short positions or derivatives, so net exposure remains unclear, but the equity book alone represents a 14% drawdown from its peak $28 billion in Q2 2023. Mandel's next public comment is expected at the Sohn Investment Conference in May 2025, where he has historically telegraphed macro views that align with his 13F positioning three months prior.